Skip to content

Endovascular Therapy Versus Best Medical Treatment for Acute Large Vessel Occlusion Stroke With Low NIHSS

Endovascular Therapy Versus Best Medical Treatment for Acute Large Vessel Occlusion Stroke With Low NIHSS

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06143488
Enrollment
264
Registered
2023-11-22
Start date
2024-02-07
Completion date
2028-03-31
Last updated
2026-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Ischemic Stroke, Mild Neurocognitive Disorder, Thrombectomy

Brief summary

Patients presenting with mild symptoms of acute ischemic stroke are common and account for approximately half of all acute ischemic stroke. About 30% of patients with minor stroke have a 90-day functional disability. Radiologically proven a large vessel occlusion (LVO) in patients with minor stroke is a well-established predictor of poor outcomes, while the poor outcomes following best medical management in patients with minor stroke with the underlying presence of a LVO are mainly driven by the occurrence of early neurological deterioration (END). Considering the well-known strong association between lack of arterial recanalization and END, endovascular therapy (EVT) appears as an attractive option to improve functional outcomes for LVO-related patients with stroke with mild symptoms. Whether EVT is safe and effective in patients with mild stroke with an LVO is currently debated, since these patients were typically excluded from the pivotal EVT trials. The current study aimed to further test the hypothesis that endovascular therapy would be superior to medical management with respect to functional recovery among low NIHSS patients caused by acute large-vessel occlusion in the anterior circulation.

Interventions

PROCEDUREEndovascular therapy

Drug: Best medical management All the patients enrolled received standard guideline-directed medical therapy including: monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic (antiplatelet or anticoagulant therapy determined by treating physician) therapy if appropriate. Procedure: Endovascular therapy In the procedure, the methods including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty and stenting can be used according to the local interventionalists' choice. Mechanical thrombectomy or aspiration thrombectomy will be recommended as the primary treatment.

All the patients enrolled received standard guideline-directed medical therapy including: monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic (antiplatelet or anticoagulant therapy determined by treating physician) therapy if appropriate.

Sponsors

First Affiliated Hospital of Wannan Medical College
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Intervention model description

Drug: Best medical management Procedure: Endovascular therapy

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Aged 18 years or older; 2. The time from onset of acute ischemic stroke to arterial puncture is within 24 hours. Onset time is defined as the patient's Last Known Well (LKW); 3. Low NIHSS score (2-5 points), with at least one of the following items: 1. Altered mental status (lethargy or worse); 2. Facial palsy (facial weakness score ≥ 1 point); 3. Motor dysfunction (limb weakness score ≥ 1 point); 4. Aphasia (language disturbance score ≥ 1 point); 5. Hemispatial neglect (neglect score ≥ 1 point); 4. Intracranial internal carotid artery, proximal M1 or M2 segment of middle cerebral artery occlusion (excluding tandem lesions) confirmed by cerebral CTA/MRA/DSA before randomization, which is identified as the culprit vessel for stroke; 5. All patients receive CTP/MR perfusion imaging, with a volume of perfusion delay (Tmax\>6 s) ≥ 50 mL; 6. Written informed consent is obtained from the patient or legal surrogate, with agreement for long-term follow-up.

Design outcomes

Primary

MeasureTime frameDescription
90-day excellent clinical outcome90±7 days after randomizationa dichotomized mRS 0-1 outcome

Secondary

MeasureTime frameDescription
Good clinical outcome90±7 days after randomizationdefined as a dichotomized mRS 0-2
early recovery72 hours after randomization72-hour NIHSS score≥4 points drop as compared with baseline

Countries

China

Contacts

CONTACTZhiming Zhou, PhD
neuro_depar@hotmail.com(++)86-(+)-553-5739543

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 1, 2026